Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) Income from Continuing Operations (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Income from Continuing Operations for 13 consecutive years, with 543000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations fell 171.92% year-over-year to 543000.0, compared with a TTM value of 204710000.0 through Dec 2025, down 113.18%, and an annual FY2025 reading of 204710000.0, down 113.18% over the prior year.
  • Income from Continuing Operations was 543000.0 for Q4 2025 at Tandem Diabetes Care, up from 21222000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 10808000.0 in Q4 2021 and bottomed at 130556000.0 in Q1 2025.
  • Average Income from Continuing Operations over 5 years is 30117600.0, with a median of 22236500.0 recorded in 2024.
  • The sharpest move saw Income from Continuing Operations skyrocketed 161.59% in 2021, then crashed 944.82% in 2022.
  • Year by year, Income from Continuing Operations stood at 10808000.0 in 2021, then tumbled by 247.06% to 15894000.0 in 2022, then crashed by 88.82% to 30011000.0 in 2023, then soared by 102.52% to 755000.0 in 2024, then crashed by 171.92% to 543000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for TNDM at 543000.0 in Q4 2025, 21222000.0 in Q3 2025, and 52389000.0 in Q2 2025.